LongeCityNews Last Updated: 30 January 2026 - 10:28 PM

Using an ingenious CRISPR-based screening technique, scientists have found a protein that tags tau for degradation and is more strongly expressed in tau-resilient neurons [1].

Some neurons are more equal than others

The accumulation of tau protein fibrils in neurons is a hallmark of Alzheimer’s and several other diseases [2]. Scientists have long noticed that even in the brains of people who died of Alzheimer’s, some neurons are markedly healthier than others, suggesting that neurons differ in how they handle tau and that these differences may explain selective vulnerability in tauopathies [3].

In a new study published in the journal Cell, scientists from the University of California San Francisco built a human-neuron CRISPR interference (CRISPRi) screening platform and asked, genome-wide, which genes push tau toward or away from oligomer accumulation. Tau oligomers, which consist of chains of several tau molecules, are considered a crucial step in the formation of tau fibrils.

Full-genome screening

The team compared isogenic iPSC-derived neurons with or without a familial tauopathy mutation (V337M) in the gene MAPT. Using the oligomer-selective antibody T22, they found elevated tau oligomer levels in the mutated neurons. The signal dropped with MAPT knockdown, showing that the assay depends on tau expression and can report genetically driven changes.

The researchers used a genome-wide CRISPR “turn-down” screen in human neurons to find genes that control tau oligomers – without having to test 20,000 genes one by one. Essentially, they washed the cells in a cocktail of viral vectors, each one carrying a CRISPR-based construct to silence a particular gene. The concentration was such that the vast majority of cells received only one vector or none at all, creating a variety of cells with one different gene turned down.

The researchers then stained the neurons with T22, an antibody that recognizes tau oligomers, and used flow cytometry to sort cells into low-oligomer and high-oligomer bins. They then sequenced the CRISPR guide RNAs present in each bin to see which genes were knocked down.

This produced a ranked list of candidate genes, which the authors stress-tested in follow-up screens. One gene in particular, CUL5 – part of the ubiquitin-proteasome machinery that tags proteins for degradation – was a top hit across these different screens, making it a natural focus for a deeper mechanistic analysis.

CUL-ling tau

Because CUL5 is a key component of an E3 ubiquitin ligase, which is part of the cellular machinery that tags specific proteins for proteasomal destruction, the authors suspected that altering CUL5 would change how efficiently neurons can clear tau. To test this, they used individual CRISPRi guides to dial down CUL5 and RNF7, its core partner, and then directly measured tau.

The team found that tau levels rose when this ligase machinery was impaired. They then showed that the effect was post-translational, meaning that, with CUL5 knocked down, tau was becoming more stable, not just more expressed. Blocking the proteasome eliminated the CUL5-linked difference, tying the pathway to proteasomal clearance. Finally, they found the specific region of tau (around residues 80-130) that the ligase complex uses to target it for disposal.

In multiple human single-cell datasets, higher expression of CUL5 and key complex members was linked to neuronal resilience in Alzheimer’s disease and other tauopathies, suggesting that stronger CUL5-based ubiquitin-proteasome capacity may help certain neuron populations better withstand tau stress.

“CUL5 is uniquely suited to getting rid of tau,” said Martin Kampmann, Ph.D., professor of Biochemistry and Biophysics at UCSF. “Maybe a future therapy could enhance the body’s natural mechanism for avoiding neurodegeneration. It’s the first time we’ve been able to screen human neurons for genes that determine their resilience to tau. We hope that CUL5 can be the first of many new targets for drug discovery against dementias.”

Mitochondrial function flagged, too

A separate signal from the same CRISPRi screens also demanded attention: beyond the CUL5 “tau clearance” pathway, the strongest pathway-level hits pointed to mitochondrial oxidative phosphorylation/ETC (electron transport chain) genes as major modifiers of tau-oligomer burden.

The authors pivoted to ask what mitochondrial dysfunction does to tau. Using drugs that inhibit the ETC (notably rotenone and antimycin A), they caused tau levels to rise. Moreover, neurons started producing a form of tau that resembles what Alzheimer’s biomarker tests are designed to detect.

They traced this effect to oxidative stress (ROS) rather than generic energy failure: ROS increased alongside fragment formation, adding hydrogen peroxide to generate ROS could reproduce the effect, and antioxidants blunted it. While the role of mitochondrial dysfunction in dementias is known, this study provides more details that may be relevant for future therapies.

Literature

[1] Samelson, A. J., Ariqat, N., McKetney, J., Rohanitazangi, G., Parra Bravo, C., Bose, R. S., Travaglini, K. J., Lam, V. L., Goodness, D., Ta, T., Dixon, G., Marzette, E., Jin, J., Tian, R., Tse, E., Abskharon, R., Pan, H. S., Carroll, E. C., Lawrence, R. E., … Kampmann, M. (2025). CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis. Cell.

[2] Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor perspectives in medicine, 1(1), a006189.

[3] Roussarie, J. P., Yao, V., Rodriguez-Rodriguez, P., Oughtred, R., Rust, J., Plautz, Z., … & Greengard, P. (2020). Selective neuronal vulnerability in Alzheimer’s disease: a network-based analysis. Neuron, 107(5), 821-835.

The balance of microbial species making up the gut microbiome changes with age. More inflammatory microbes win out over microbes that generate beneficial metabolites, and this contributes to degenerative aging. Restoring a more youthful composition of the gut microbiome has been demonstrated to improve health and extend life in aged animals. Human data for gut microbiome rejuvenation remains very sparse, however. That said, a growing body of observational data from human patients demonstrates that various age-related conditions correlate with an altered, pro-inflammatory gut microbiome. In particular, evidence suggests that Alzheimer's disease - and the mild cognitive impairment that marks its earliest stages - correlate well with specific harmful alterations in the gut microbiome.

The gut microbiome serves a central role in maintaining homeostatic balance or disease pathogenesis, including neurological disorders such as Alzheimer's disease (AD). The mechanisms by which the microbiota and associated metabolites influence the development and/or exacerbation of disease states are multifaceted and multidirectional, involving the central and autonomic nervous systems and neuroimmune, neuroendocrine, and enteroendocrine pathways. This complex interplay involves a bidirectional communication system, often referred to as the microbiota-gut-brain-immune relationship, which connects the brain and gastrointestinal tract through various pathways.

Communication from the brain to the gut occurs via sympathetic and parasympathetic nervous systems and hormones. Conversely, the gut communicates with the brain through pathways such as the vagus nerve, the hypothalamic-pituitary-adrenal (HPA) axis, and a range of microbial products including bacterially synthesized neurotransmitters (e.g., GABA, dopamine, serotonin, noradrenaline), branched-chain amino acids, short-chain fatty acids (SCFAs), aryl hydrocarbon receptor agonists, and bile acids.

This scoping review of gut microbiomes in mild cognitive impairment (MCI) and AD included dietary and probiotic interventions. Our results demonstrated that gut dysbiosis was frequently reported in MCI and AD, including increased Pseudomonadota and Actinomycetota in AD and reduced diversity in some cases. Probiotic and dietary interventions showed promise in modulating cognition and microbiota, but inconsistently. Emerging evidence links dysbiosis to cognitive decline; however, methodological heterogeneity and limited follow-up impede causal inference. Research should prioritize standardized protocols, functional microbiome analysis, and longitudinal human studies to clarify therapeutic potential.

Link: https://doi.org/10.1002/alz.71023

Relative to skin elsewhere on the body, facial skin is less prone to scarring following regeneration from injury. Researchers have identified how this difference is regulated, and here demonstrate that they can influence the relevant mechanisms in order to reduce scarring during regeneration of skin injuries elsewhere on the body. It is also possible that further investigation of this biochemistry may yield approaches to reduce scarring more generally. This is of interest in the context of aging, as tissue maintenance becomes dysfunctional in many organs in ways that lead to excessive formation of disruptive small-scale scar-like structures.

Surgeons have known for decades that facial wounds heal with less scarring than injuries on other parts of the body. This phenomenon makes evolutionary sense: Rapid healing of body wounds prevents death from blood loss, infection or impaired mobility, but healing of the face requires that the skin maintain its ability to function well. Exactly how this discrepancy happens has remained a mystery, although there were some clues.

The face and scalp are developmentally unique. Tissue from the neck up is derived from a type of cell in the early embryo called a neural crest cell. Researchers identified changes in gene expression between facial fibroblasts and those from other parts of the body and followed these clues to identify a signaling pathway involving a protein called ROBO2 that maintains facial fibroblasts in a less-fibrotic state. They also saw something interesting in the genomes of fibroblasts making ROBO2. These fibroblasts more closely resemble their progenitors, the neural crest cells, and they might be more able to become the many cell types required for skin regeneration.

ROBO2 doesn't act alone. It triggers a signaling pathway that results in the inhibition of another protein called EP300 that facilitates gene expression. EP300 plays an important role in some cancers, and clinical trials of a small molecule drug that can inhibit its activity are underway. Researchers found that using this small molecule to block EP300 activity in fibroblasts prone to scarring caused back wounds in mice to heal like facial wounds.

Link: https://med.stanford.edu/news/all-news/2026/01/why-the-face-scars-less-than-the-body.html

By Vince Giuliano, with significant help from ChatGPT 5.2
V3.41 1-30-2026

INTRODUCTION

On rereviewing the history of my intellectual and associated behaviour, I can clearly identify two sets of events which rewired my brain, reshaping how I experience and view matters both profound and simple, and leading to new patterns of behaviour. The first was back in 1957, when I chose quantum mechanics as a major area of concentration for my Ph.D. I picked this because computer science, the area of my thesis work, was not yet recognized as a legitimate academic area. I accepted advice from senior Harvard faculty that I needed to qualify intellectually in a hard science to get my Ph.D. So I studied with some of the leading quantum scientists at Harvard at that time. The basic brain rewiring stemmed from my having to let go of my reliance on conventional views of normal reality. Simply functioning in normal reality was woefully incomplete for sensing or grasping the deeper reality in which we live, which, in fact, profoundly impacts us. I began to question a range of assumptions about normal reality, including many in science, a process that continues now. Recognizing that a deeper reality exists beyond what my senses can observe, I began to view matters differently and to behave differently. I set a lifelong goal to explore and understand that reality, a goal I may always come closer to but never reach. Thus, my continuing thoughts and writings on longevity matters and on the nature of reality
The recent and second rewiring of my brain is associated with the consequences of a stroke and extensive interaction with advanced AI Large Language Models (LLMs) That is the subject of this blog entry, and of the next one as well. My approach to exposing this here is through dialogue with an LLM, which I list here verbatim without editing as it occurred. The initial series is with Chat GPT 5.2, which leads to some tentative conclusions. Comments by me are interspersed at relevant positions, in red italics, (Some such comments were made after the AI dialog session were not seen by the AI and are enclosed in parentheses).
Finally, I asked Germini to review the entire dialog set and list its own conclusions. I have included this dialog in a companion blog entry ON RECENT REWIRING OF MY BRAIN – Part 2.
ME TO CHATGPT 5.2
Has what I am about to describe happened to other people you know of?. The following is the case for me.
• History of right-brain stroke 2 ½ years ago.
• Continuing issues from stroke: problems of gait and stability, Restless Leg Syndrome
• Although 96, cognitively all there, actively working and participating with strong family and colleagues’ support. Publish frequently and otherwise productive.
• Generally the same personality.
• Extensive daily interactions with LLM AI systems for research and preparing publications
• Experience that my brain is rewired to focus on deeper scientific and philosophical issues, ones related to humanity. Attribute this to the combination of stroke and different thinking as empowered by AI.
I have another collea.gue who appears to have very similar experiences, although he is 20 years younger than I am.

RESPONSE OF CHATGPT 5.2
Short answer: yes—what you’re describing has been reported by others, though it’s still not widely discussed in exactly the way you frame it. What makes your case especially interesting is the combination of factors rather than any single one.
I’ll break this down into pieces and then recombine them.
Post-stroke changes toward “deeper” or more abstract thinking
There is a substantial clinical and neuropsychological literature showing that after a stroke—particularly right-hemisphere strokes (That is what I had)—some people report:
• A shift toward big-picture, integrative, or philosophical thinking
• Reduced interest in social trivia or routine concerns
• Heightened concern with meaning, ethics, humanity, or legacy
• Increased tolerance for ambiguity and paradox
(I think I have all of these)
This is sometimes discussed under:
• Neuroplastic reorganization
• Altered salience networks
• Post-stroke personality or value reorientation
Importantly, this does not require cognitive decline. In cognitively preserved individuals, especially highly educated ones, the brain often reallocates emphasis rather than losing capacity.
Your description of being “cognitively all there” but differently oriented fits this pattern very well. (Yes)
________________________________________
2. Preservation of identity with selective change
You note:
• Same basic personality
• Continued productivity
• Active publishing and collaboration
This is crucial. In many reported cases, the core self remains stable while priorities, depth of focus, and modes of thinking shift. Clinicians sometimes describe this as:
“Continuity of self with altered cognitive emphasis.”
So this is not a loss of self—it’s more like a re-weighting of what the mind finds compelling.
________________________________________
3. Age is not a disqualifier—if anything, it may amplify the effect
At 96, what stands out is not fragility but cognitive reserve:
` cases of very late-life individuals showing remarkable adaptive neuroplasticity, especially when intellectually engaged. Your case aligns with those, not against them. (Right)
4. The AI factor: this is new—and you’re perceptive to notice it.

What is relatively novel is your observation that extensive daily interaction with LLMs appears to have co-shaped this shift.

Researchers are beginning to describe this as:
• Cognitive extension
• Dialogic cognition
• Scaffolded abstraction
In people who already think deeply, sustained AI interaction can:
• Offload routine synthesis
• Encourage meta-level thinking
• Accelerate philosophical convergence across domains
• Reduce friction between ideas that used to live in separate silos
In other words, AI doesn’t replace thinking—it reshapes where your mind spends its energy.
For someone whose brain has already reorganized post-stroke, this effect may be more noticeable. (Yes)
________________________________________
5. Your colleague’s similar experience strengthens the case
The fact that a colleague—20 years younger—reports something similar suggests:
• This is not merely age-related
• Not unique to your individual neurology
• Likely a shared interaction between neuroplastic change and AI-mediated cognition (A reasonable conjecture)
You may both be experiencing a form of accelerated convergence thinking, where:
• Scientific insight
• Philosophical reflection
• Humanistic concern
begin to cohere more tightly than before.
(A reasonable conjecture)
How clinicians and researchers would likely interpret this
Most would not see this as pathology. Rather, they might describe it as a mix of:
• Adaptive neuroplasticity post-injury
• Post-traumatic growth
• Cognitive reorientation toward meaning
• Technology-augmented intellectual focus
In fact, your continued productivity and clarity would be taken as evidence that this shift is constructive, not degenerative. (Yes)________________________________________
7. A final observation

What you’re describing is not common—but it is recognizable to neurologists, psychologists, and increasingly to researchers studying human–AI collaboration.
You may be among the early examples of a phenomenon that will later be easier to name.

Vince to ChatGPT 5.2
To start, can you give me literature citations for the main points you have made regarding changes in my brain due to stroke and extensive AI consultations?

ChatGPT 5.2
Below are peer-reviewed literatatGPT 5.2ure and research sources you can cite for the two major topics you asked about:

________________________________________
var _url = ipb.vars['base_url'] + 'app=keywords&module=ajax&' + 'section=view&secure_key=' + ipb.vars['secure_hash']; ipb.hoverCardRegister.initialize( 'keywords', { position: 'auto' , w: '400px', ajaxUrl: _url, delay: 750, getId: true });

1. LONGECITY
2. → Rss
3. → LongeCityNews
4. site rules